Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K033599
    Manufacturer
    Date Cleared
    2004-09-16

    (307 days)

    Product Code
    Regulation Number
    886.5916
    Reference & Predicate Devices
    N/A
    Why did this record match?
    Device Name :

    ONSI -56 (ONSIFOCON A) RIGID GAS PERMEABLE SPHERICAL, ASPHERIC, TORIC AND BIFOCAL CONTACT LENS

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The ONSIJ-56 (onsifocon A) Rigid Gas Permeable Spherical, Aspheric, Toric and Bifocal Contact Lens is indicated for daily wear for the correction of visual acuity in not-aphakic persons with non-diseased eyes that are myopic, hyperopic or presbyopic and which may exhibit corneal astigmatism.

    The lenses may be disinfected only by using chemical disinfection

    Device Description

    The ONSI™-56 (onsifocon A) Rigid Gas Permeable Spherical, Aspheric, Toric and Bifocal Contact Lenses are available in spherical designs in the clear untinted or blue, green, gray, or blue-violet tinted varieties and blue tint with UV-blocker. Each is a shell of the following dimensions.
    Spherical Contact Lens:
    Horizontal Lens Size: 6.5 mm to 11.50mm
    Base Curve: 6.50mm to 9.50mm
    Distance Powers: +12.00D to -20.00D
    Center Thickness:
    for low minus 0.05mm to 0.30mm
    for plus 0.10mm to 0.70mm
    Aspheric Lens
    Eccentricity 0 to 1.5
    Peripheral Curves 0.1 to 1.0mm
    Toric Lens
    Axis 1 to 180 degrees in 1 degree steps
    Cylinder power 0.50 to 4.00D
    Translating Bifocal Contact Lens:
    Horizontal Lens Size: 8.00mm to 10.50mm
    Base Curve: 6.50mm to 8.50mm
    Distance Power: +12.00D to -20.00D
    Add Power 1.00 to 4.00D
    The lens material, onsifocon A, is trifluoroethyl methacrylate polymer with tris (trimethylsiloxy)methacryloxypropylsilane 3-trimethoxysily|propylmethacrylate methacrylic acid 1,3-bis(3- methacryloxypropyl)tetrakis(trimethylsiloxy)disiloxane ethylene glycol dimethacrylate 2-hydroxyethyl methacrylate N-vinylpyrrolidone. The blue tinted lenses contain D&C Green No. 6; the green lenses contain D&C Green No 6 and CI Solvent Yellow 18; the gray lenses contain D&C Green No 6, D&C Violet No. 2, and CI Solvent Yellow 18; the blue-violet contain D&C Green No. 6 and D&C Violet No. 2; the blue-UV lenses contain D&C Green No 6 and a UV absorber, NORBLOC 7966. The colorants are used in quantities approved for use in contact lenses and proportions required to obtain the desired color.

    AI/ML Overview

    Here's a summary of the acceptance criteria and study findings for the ONSI™-56 (onsifocon A) Rigid Gas Permeable Contact Lens, based on the provided 510(k) summary:

    1. Table of Acceptance Criteria and Reported Device Performance

    The 510(k) summary does not explicitly list "acceptance criteria" for the clinical study in a quantitative manner (e.g., minimum visual acuity improvement, maximum complication rate thresholds). Instead, it describes general safety and efficacy findings. The tables below summarize the product's physical properties compared to a predicate device and the clinical study findings:

    Comparison to Predicate Device (Oxycon (wilofocon A))

    CharacteristicPredicate Device (Oxycon)ONSI™-56 (onsifocon A)
    Water Content95% T
    Light Transmittance (Tinted)93% (green), 87% (gray)>70% T (blue, green, gray, blue-violet, blue UV)
    Light Transmittance (Blue UV)(not specified)>70% T (400-780nm), 0% T (200-380nm)

    Clinical Study Findings (Safety and Efficacy)

    Finding / MetricInitial (Baseline)Final (3 Months)General Observation / Interpretation
    No Findings (Slit Lamp)90.5% (eyes)Not directly comparable (table shows "वेरे '8") - Likely a typo, assuming "reported as high" based on conclusionHigh percentage of eyes with no adverse slit lamp findings.
    Edema0.0%0.0%No incidence of edema related to the lenses.
    Neovascularization1.4%0.0%Slight decrease in pre-existing neovascularization. Good safety.
    Staining5.4%3.2%Decrease in corneal staining incidence over time.
    Hyperemia1.4%0.0%Elimination of hyperemia during the study.
    Palpebral Abnorm.1.4%0.0%Elimination of palpebral abnormalities during the study.
    Adverse EventsN/A0 (zero)No unanticipated adverse device effects observed during the study.
    No Symptoms (Scheduled visits)N/A75.7% (eyes)A high percentage of eyes reported no symptoms.
    Lens AwarenessN/A5.7%Low incidence of lens awareness.
    Reading ProblemsN/A5.5%Low incidence of reading problems.
    Need for CleaningN/A5.2%Low incidence of need for cleaning.
    DrynessN/A4.6%Low incidence of dryness.
    DiscontinuationsN/A1 subject (3%)Very low discontinuation rate, indicating good patient tolerance.
    Visual AcuityBaselineFinalAll eyes had a final visual acuity within 1 line of the initial best corrected acuity. (Efficacy met)
    Wear TimeBaseline3 MonthsRemained essentially unchanged, indicating continuing comfort and cleanliness. (Efficacy met)
    Lens ReplacementsN/A10 (6 for VA)Low number of replacements, mostly for VA in the first month, supporting efficacy for myopia.

    2. Sample Size and Data Provenance

    • Test Set Sample Size: 37 subjects.
    • Data Provenance: The 510(k) summary does not explicitly state the country of origin. It is a clinical trial, implying prospective data collection.

    3. Number of Experts and Qualifications for Ground Truth (Test Set)

    • Number of Experts: Not explicitly stated, but the study involved "Three (3) investigators." These investigators would have been responsible for clinical assessments (e.g., slit lamp findings, visual acuity measurements), and thus contributed to establishing the "ground truth" through their clinical observations and measurements.
    • Qualifications of Experts: Not explicitly stated, but for a contact lens clinical trial, these investigators would typically be ophthalmologists, optometrists, or other eye care professionals experienced in contact lens fitting and evaluation, often with significant clinical experience.

    4. Adjudication Method (Test Set)

    • The 510(k) summary does not describe any formal adjudication method (e.g., 2+1, 3+1). The findings are reported as collected by the investigators.

    5. Multi Reader Multi Case (MRMC) Comparative Effectiveness Study

    • No, an MRMC comparative effectiveness study was not done. The clinical study compared the ONSI™-56 device to "historical controls wearing wilofocon A," rather than a concurrent study with human readers comparing AI-assisted vs. non-AI-assisted performance. This is a direct device performance study.
    • Effect Size: Not applicable, as no MRMC study was conducted.

    6. Standalone (Algorithm Only) Performance

    • No, a standalone (algorithm only) performance study was not done. This device is a physical contact lens, not a software algorithm. Therefore, "algorithm only" performance is not applicable. The study evaluated the lens's performance in human subjects.

    7. Type of Ground Truth Used

    • The ground truth for the clinical study was established through expert clinical assessment and objective measurements by the investigators. This included:
      • Slit lamp findings (presence/absence and severity of conditions like edema, neovascularization, staining, hyperemia, palpebral abnormalities).
      • Visual acuity measurements.
      • Patient-reported symptoms, problems, and complaints.
      • Wear time.
      • Lens replacements.

    8. Sample Size for the Training Set

    • Not applicable. This study is for a physical medical device (contact lens) and not an AI/ML algorithm. Therefore, there is no "training set" in the context of machine learning.

    9. How the Ground Truth for the Training Set Was Established

    • Not applicable. As there is no training set for an AI/ML algorithm, this question is not relevant to this device submission.
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1